National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Volasertib Research Grant Opportunity – Submit by October 30, 2014
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources


Duke Cancer Institute
Durham, North Carolina
888.275.3853 (888.ASK.DUKE)
dukecancerinstitute.org

Adult Oncology Services

Introduction

Since its inception in 1972 as one of the nation's first comprehensive cancer centers, the Duke Cancer Institute (DCI) has been at the forefront of efforts to understand, prevent, diagnose, and treat cancer through patient care, clinical research, laboratory investigation, and education. Every activity the DCI undertakes-from basic research to clinical trials to educational programs-is aimed at improving the care of cancer patients.

The Duke Cancer Institute is a matrix center-one that draws upon the depth of basic scientific research and clinical expertise.

The "comprehensive" status from the National Cancer Institute recognizes the center for its excellence in research and for other contributions in the areas of clinical trials, prevention and control efforts, information and educational offerings, and outreach and service activities. Duke Cancer Institute's more than 350 physicians and scientists research all aspects of cancer biology and treatment.

General Information

General Information

Call 888.275.3853 (888.ASK.DUKE). After hours, you may leave a message and your call will be returned the next business day.

Referring Physician Line

For adult and pediatric oncology call, 800.633.3853 (800.MED.DUKE)

Location

Durham, North Carolina

Facility

  • Oncology inpatient units are housed together on one floor of Duke Hospital, with more than 100 beds dedicated solely to cancer care. There are specialized units for adult and pediatric bone marrow transplant.
  • Most cancer outpatient services are provided in the Duke Cancer Center, a 267,000 square foot building that opened in 2012 and is adjacent to Duke Hospital.
  • The outpatient and marrow processing facilities of the combined adult and pediatric Blood and Marrow Transplant Program are located on the first floor of North Pavilion, located two blocks from the hospital.
  • A five-story, 65,000 square foot McGovern-Davison Children's Health Center (CHC) houses pediatric oncology activities.
  • The administrative and basic research facilities of the Duke Cancer Institute occupy over half a million square feet of space throughout the Medical Center.

Travel Assistance

919.681.2020

Lodging

Many hotels and motels are within walking distance to Duke Hospital, or offer shuttle service. Some offer discounts to out-of-town family and friends. Call Patient and Visitor Relations at 919.681.2020 or 888.ASK.DUKE for more information.

The Host Homes Program provides accommodations for family members in local homes at minimal or no cost while the patient is undergoing treatment. Family members should provide their own transportation. Contact the Host Homes desk at 919.681.4688.

The Ronald McDonald House provides a home where families can stay while their children are receiving treatment at Duke Medical Center for serious illnesses. For further information on admission procedures call 919.286.9305 or go to www.ronaldhousedurham.org.

Caring House is available to adult out-of-town cancer outpatients. The facility provides comfortable, home-like accommodations; outpatients may bring a family member to stay with them. For more information, please call 919.490.5449 or go to www.caringhouse.org. For referrals to Caring House, contact an oncology social worker at 919.668.6676.

Treatment

Multidisciplinary Teams

Description

Adult Blood and Marrow Transplant Program

Duke’s Adult Blood and Marrow Transplant Program is internationally recognized for its novel approaches to treating leukemia, lymphoma, and myeloma through bone marrow, cord blood, and peripheral blood-progenitor-cell transplantation—also being used as novel therapies for some autoimmune diseases and hemoglobinopathies. Our board-certified physicians include intensivists in stem-cell transplantation, hematology/oncology, medical oncology, and related specialties.

Duke’s leadership in investigating stem-cell transplantation enables patients to be treated with the very latest approaches—of special importance to those with refractory or recurrent malignancies. Acclaimed for their extensive studies of transplantation used in conjunction with treatments such as immunotherapy, vaccine therapy, and the novel drugs, our researchers are striving to improve transplantation outcomes and reduce complications such as graftversus-host disease.

Bone Marrow/Stem Cell Transplantation

Duke has earned national and global recognition for its leadership in bone marrow and stem cell transplantation. The adult program is renowned for its pioneering efforts in the treatment of breast cancer with autologous bone marrow/stem cell transplantation and innovative approaches to the treatment of leukemia, lymphoma, and myeloma. Duke is also recognized for its extensive research into a variety of treatment modalities that can be combined with transplantation. These include immunotherapy, anti-angiogenesis therapy, and the latest chemotherapy and pharmacologic therapies.

Brain Tumors

The Preston Robert Tisch Brain Tumor Center at Duke (cancer.duke.edu/btc), established in 1937, is one of the nation’s oldest and largest brain-tumor clinical and research programs. Dedicated entirely to treating and discovering cures for brain, skull-base, and spinal tumors in children and adults, the center combines the resources of a leading research program with a commitment to delivering the best in patient care. Duke currently follows more than 2,200 adult and pediatric patients with brain tumors from all over the world and is committed to improving and extending their survival.

Breast Cancer

Breast oncology specialists at the DCI offer women a complete range of services—from diagnostics to genetic and prevention counseling to state-of-the-art treatments for all stages of disease. The multidisciplinary care team includes medical, surgical, and radiation oncologists who meet weekly to discuss individual cases and to formulate and review treatment plans.

Specially trained in breast imaging, our radiologists use the most advanced technologies and techniques to detect and diagnose breast cancer. They are skilled in all minimally invasive biopsy techniques, including needle core biopsies performed with stereotactic and ultrasound-guided surgery and pre-surgical wire localizations.

Duke has ongoing opportunities for patients with all stages of breast cancer to participate in clinical trials.

Gastrointestinal Cancer

DCI gastrointestinal cancer specialists treat patients with cancers of the esophagus, stomach, pancreas, liver, biliary system, small intestine, colon, anus, and rectum—including uncommon tumors such as anal, neuroendocrine, and gastrointestinal stromal tumors.

Patients from around the world choose Duke for the individualized care, state-of-the-art treatments, surgical experience, and opportunities to participate in clinical trials.

The DCI’s five board-certified colorectal surgeons—far more than any other hospital in the region—specialize in laparoscopic colon and rectal surgery, as well as sphincter-preserving operations for low rectal cancers. Our radiation and medical oncologists have special expertise in areas that include intra-operative radiation therapy, neoadjuvant therapy of rectal cancer, and phase 1 and 2 clinical trials of therapies for these malignancies.

Our specialists see up to 200 patients with esophageal cancer each year—significantly more than other hospitals.

Gynecologic Cancer

Gynecologic oncology specialists at the DCI treat ovarian, endometrial, and cervical cancers—and improve the survival of women suffering from these diseases.

Our multidisciplinary team offers the latest approaches in surgery, chemotherapy, radiation, brachytherapy, and supportive care in a patient-centered environment that emphasizes emotional support for patients and families. Our physicians are experts in hereditary gynecologic cancers and leaders in adapting laparoscopic and robotic surgical approaches to the treatment of gynecologic cancers, offering these services at Duke University Medical Center and Duke Raleigh Hospital.

Head and Neck Cancer

DCI head and neck cancer specialists evaluate and treat cancers of the mouth, salivary and thyroid glands, nasal cavity, paranasal sinuses, pharynx, larynx, and lymph nodes.

Our internationally recognized physicians have helped develop innovations that are now the standards of care in treating head and neck cancers. These include combining intensive radiation therapy with chemotherapy for advanced-stage head and neck cancers and developing surgical techniques that result in better function and less disfigurement.

Supported by the most advanced technologies available, our team includes specialists in head and neck oncologic surgery, plastic and reconstructive surgery, radiation oncology, medical oncology, radiology, and pathology. All work to ensure that each patient receives the safest, most appropriate care while maintaining optimal quality of life throughout treatment and recovery.

Hematologic Malignancies

Hematologic malignancy specialists at the DCI combine state-of-the art, compassionate medical care with innovative science to improve outcomes for patients battling lymphoma, leukemia, myeloma, myelodysplasias, myeloproliferative disorders, aplasia, and other neoplastic diseases of the marrow or blood system. Patients are treated within a matrix of support, with the care team of physicians, nurses, nurse practitioners, physician assistants, and pharmacists discussing cases daily.

Many of the therapies we offer for leukemias and lymphomas have been developed and refined at Duke, and patients can access novel treatments through an extensive array of clinical trials.

Duke hematopathologists can go beyond standard diagnostics tomonitor leukemia and lymphoma patients at the molecular level by using fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), and genomic techniques. Specialists in medicine, surgery, radiation therapy, and stem cell and marrow transplantation meet regularly to review difficult cases, debate new therapy plans, and formulate treatment algorithms.

Lung Cancer

Duke Cancer Institute’s dedicated thoracic specialists offer a multidisciplinary approach to ensure that each patient benefits from the combined expertise of our caregivers in medical oncology, thoracic surgery, radiation oncology, pulmonary medicine, and genetics. Duke thoracic oncology surgeons are national leaders in minimally invasive surgical procedures such as thoracoscopic lobectomy.

Our radiation oncologists focus on lung cancer and have access to specialized techniques such as stereotactic radiation therapy for early-stage lung cancer, as well as radiation-treatment planning aided by 4-D CT technology, which tracks tumor motion caused by breathing. Duke’s medical oncologists have developed a portfolio of targeted therapies, novel agents, and immune approaches that are integrated in multidisciplinary protocols with surgery and radiation.

Duke has launched a screening program to give people at high risk for lung cancer access to spiral computed tomography (CT) scans, the most advanced screening available for the disease.

Melanoma

DCI melanoma specialists deliver the full spectrum of care—from screening and surveillance to management of primary disease to treatment for recurrent and metastatic disease. We offer systemic treatment to patients with advanced or progressing melanoma, including high-dose interleukin-2 (IL-2), multi-agent chemotherapy, novel treatments, and investigational agents available only through clinical trials.

Duke is one of a limited number of cancer centers in the Southeast offering high-dose interferon alpha, a therapy used to prevent recurrences in patients with stage 2 and stage 3 melanoma. We also conduct clinical trials testing new ways to use interferon-cased and vaccine therapies to prevent recurrences in patients with stage 2 and stage 3 melanoma.

Mole-mapping technology—pioneered by Duke researchers and now used worldwide—allows physicians to detect the earliest signs of melanoma by maintaining and monitoring photographic records of the skin. Duke also has dermatopathologists who review every tumor.

Prostate/Genitourinary Cancer

Duke offers one of the country’s premier comprehensive treatment, training, and research programs for prostate cancer and other genitourinary cancers, including bladder, renal, and testicular cancers. Duke’s experienced physicians focus on diagnosing and treating genitourinary cancers while preserving normal function.

Prostate cancer specialists form a multidisciplinary team to deliver state-of-the-art treatment options in urology, radiation oncology, and medical oncology, as well as emerging investigative treatments based on basic, translational, and clinical research.

The hospital’s surgical volume for radical prostatectomy is among the nation’s top ten. Our team performed more than 600 radical prostatectomies in fiscal year 2011—and offers both a minimally invasive open, nerve-sparing technique and a robot-assisted surgery.

Many prostate cancer patients access the latest novel therapies through enrollment in clinical trials. Duke is one of only 13 institutions nationwide selected to participate in the Department of Defense Prostate Cancer Clinical Trials Consortium, which facilitates enrollment in phase 1 and phase 2 clinical trials to improve drug development for prostate cancer.

Sarcoma

Sarcoma specialists treat sarcoma patients of all ages, with tumors in all locations, to provide the most advanced care available for this rare disease. The team works together to create the most effective treatment plan for each individual, using both standard procedures and the latest innovative techniques, many developed at Duke. Our physicians see approximately 300 new patients with sarcomas per year, many who travel from across the country to benefit from Duke’s unique multidisciplinary approach.

Duke continues to lead the way in studying sarcoma in both children and adults. Investigational areas include developing new agents for rhabdomyosarcoma and other sarcoma subtypes and novel approaches to understand how sarcomas develop and metastasize.


Multidisciplinary Clinics

Disease Center

Contact Number

Adult Blood and Marrow Transplant

919.668.1002

Breast Cancer

919.668.6688 (Durham)

919.954.3050 (Raleigh)

Brain Tumors

919.684.5301

Gastrointestinal Cancer

919.668.6688 (Durham)

919.954.3050 (Raleigh)

Gynecologic Cancer

919.684.3765 (Durham)

919.954.3096 (Raleigh)

Head and Neck Cancer

919.668.6688 (Durham)

919.954.3096 (Raleigh)

Hematologic Malignancies

919.684.8964 (Durham)

919.954.3050 (Raleigh)

Lung Cancer

919.668.6688 (Durham)

919.954.3050 (Raleigh)

Melanoma

919.668.6688 (Durham)

919.954.3050 (Raleigh)

Prostate/Genitourinary Cancer

919.668.8108 (Durham)

919.954.3050 (Raleigh)

Sarcoma

919.613.5550 (Durham)

919.954.3050 (Raleigh)

Integrative Medicine
Physicians, clinicians, and therapists at Duke Integrative Medicine (dukeintegrativemedicine.org) deliver an array of evidence-based therapies and services to complement all types of traditional cancer treatments. These include acupuncture and massage, to alleviate nausea, pain, tissue inflammation, fatigue, and anxiety, as well as training in stress-reduction techniques that can reduce pain and anxiety and enhance treatment effects.

Preserving Fertility
The Duke Fertility Center (dukefertilitycenter.org) offers fertility preserving services such as sperm and embryo bankingfor patients undergoing cancer treatment that may affect their reproductive abilities.

Cancer Prevention and Screening
Established in 1991, Duke's Cancer Prevention, Detection, and Control Research Program explores genetic and environmental factors that increase risk for cancer, and evaluates interventions to promote behaviors that can prevent cancer, lead to its early detection, and help patients cope with cancer treatment. Program goals are to develop, evaluate, and disseminate interventions to improve the early detection of cancer and promote behaviors that can prevent cancer and to identify genetic and environmental risk factors for cancer. Program activities include:

Support Services

The Duke Center for Survivorship encompasses the services of Duke's Cancer Patient Support Program, Oncology Recreation Therapy, and Duke's Cancer Education Program. Therapy, support, and education resources are offered to patients by professionally trained counselors and hundreds of volunteers.

The Center provides support groups and individual counseling as well as image enhancement services to cancer patients and their families. Music, games, crafts, and laughter are used to optimize functioning, coping, and quality of life during treatment. Through the center, popular hobbies such as genealogy research, painting, woodworking, tiling, flower arranging, and more are provided to survivors as both an emotional outlet and recreation. Multimedia information is provided to help survivors and their families understand their treatment options, make decisions, manage the effects of cancer and treatments, and find meaning in the experience. Books, audiotapes, videotapes, and online computer resources are available in the Resource Center.

Duke Cancer Patient and Family Support Programs

Duke Center for Cancer Survivorship

919.684.8571

Duke Cancer Patient Support Program

919.684.4497

Oncology Recreation Therapy Program

919.681.2928

Resource Center

919.613.6275

Oncology Social Work Program

919.668.6676

Brain Tumor Family Support Program

919.684.5301

Support Groups:

* Art Therapy

* Breast & Gynecologic Cancer Support Group

* Caregiver Support Group

* Gastrointestinal & Pancreatic Cancer Support Group

* Genitourinary Cancers Support Group

* KidsCan! Support Group

* Leukemia, Lymphoma, and Multiple Myeloma Support Group

* Look Good...Feel Better® Program

* Mind-Body Approaches to Coping with Cancer

* Prostate Cancer Support Group

* Thoracic Oncology Support Group

Nutrition Service

The Duke Health and Fitness Center, part of the Duke Center for Living, offers a program specifically to support cancer patients upon diagnosis, during, and after treatment. The C.A.R.E. program-Cancer and Regular Exercise-includes access to the Health and Fitness Center facilities and classes, an exercise program tailored to your goals and limitations, mind-body classes, and wellness lectures. Individualized nutritional counseling is also available. Call 919.660.6660 for more information or online at www.dukefitness.org.

Cooperative Group Membership

Cooperative Group Membership List

  • CALGB
  • GOG
  • NSABP
  • RTOG
  • ACOS-OG
  • COG

Activities in Cooperative Groups

Active participation in CALGB disease specific committees by faculty.

Average Number of Adult Clinical Trials

The Cancer Center has approximately 850 therapeutic and non-therapeutic clinical trials.

Clinical and Research Efforts

Duke is a member of the National Comprehensive Cancer Network (NCCN) and is the headquarters for the biostatistics group and data management group for The Cancer and Leukemia Group B (CALGB) and the overall headquarters for the American College of Surgeons Oncology Group (ACOSOG).

Information below is for adult cancer care at Duke University Hospital only.

No. of Inpatient Beds (Medical/Surgical)

No. of Discharges

Average Length of Stay

No. of Outpatient Encounters

No. of Oncologists (Medical and Surgical)

62 dedicated medical oncology
16 adult bone marrow transplant

More than 9,000 inpatient discharges per year

6.25 days

More than 250,000 per year

125